Vadim Tarasov, director of the Institute for Translation Medicine and Biotechnology, told Sputnik that the university has completed a trial of the vaccine developed by the Gamaleya Institute of Epidemiological Research Center in Moscow.
According to a report in Sputnik News, the Russia’s Sechenov University has successfully completed human trials of the Novel Coronavirus vaccine.
According to the report, Tarasov said that the first group of volunteers would be discharged on 15 July and the second group on 20 July. The first group of 18 volunteers received the vaccine on 18 June.
And a second group of 20 volunteers received the vaccine on 23 June at the Center for Practical Research for International Cardiology.
The test was approved by the Russian Ministry of Health on 16 June.
Pfizer Inc and BioNTech SE’s vaccine candidates are expected to be ready to seek regulatory approval by the end of 2020, according to reports.
Globally, Covid-19 has more than 1.2 crore confirmed cases. 5.6 lakh people have died so far.
Gilead sciences said that an analysis on July 10 showed that its antiviral remdesivir helped to reduce the risk of death in critically affected covid-19 patients.
But cautioned that rigorous clinical trials are needed to confirm the benefit.
Gilead Sciences Oxford University researcher and American biotech company Modern is considered to be at the forefront of developing vaccines against the Novel corona virus.
